We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Team to Evaluate 505(o)(4) Safety Information for Drug Labeling Changes
FDA Team to Evaluate 505(o)(4) Safety Information for Drug Labeling Changes
July 27, 2011
The FDA plans to use a multidisciplinary team to assess new safety information about a drug and determine whether it warrants a change in the product labeling, a draft guidance says.